Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1530)	9/27/2004 3:39:43 PM
From: tom pope	Respond to of 1826

From Briefing. It's all I could find, no other fuller article 12:50 ET MGI Pharma updates Y04 outlook; guides for Y05 (MOGN) 28.00 -0.67: -- Update -- Co reaffirms Y04 Aloxi injection sales of $140-150 mln; reaffirms license revs of approx $3 mln. Co sees total sales in the range of $170-180 mln, Reuters consensus is $188 mln. Co reaffirms outlook of cost of product sales as approx 31% of sales revs. Co now sees R&D expense of approx $40 mln (excluding an estimate of one-time in-process R&D and nonrecurring transaction expense of $96 mln), on 7/14 expected R&D expense to be approx $24 mln, inclusive of milestones associated with current product candidates. Sees a loss before income and taxes of $85 mln. For Y05 co expects revs of approx $280 mln, Reuters consensus is $291.5 mln.